Romilkimab Biosimilar - Anti-IL13, IL4 mAb - Research Grade
Source
IMGT/mAb-DB 794
Species
Human
Molecular weight
LC: 36kDa HC: 63kDa
Purity
>85%
Buffer
PBS pH7.5
Delivery condition
Blue ice (+4°C)
Delivery Time
3-5 days if in stock; 3-5 weeks if production needed
Storage condition
4°C for short term; -20°C for long term
Brand
ProteoGenix
Aliases /Synonyms
Romilkimab,Romilkimab,IL13, IL4,anti-IL13, IL4
Reference
PX-TA1027
Note
For research use only. Not suitable for clinical or therapeutic use.
Isotype
[VH-VH' Gamma1 + VL-VL' kappa (bispecific)
Clonality
Monoclonal Antibody
Description of Romilkimab Biosimilar - Anti-IL13, IL4 mAb - Research Grade
General information about Romilkimab
Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralizes IL-4/IL-13 making it ideal for exploration in fibrosis, This product is for research use only.
SDS-PAGE for Romilkimab Biosimilar - Anti-IL13, IL4 mAb
Romilkimab Biosimilar - Anti-IL13, IL4 mAb, on SDS-PAGE under non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.
Reviews
There are no reviews yet.
REVIEW YOUR PRODUCT
Be the first to review “Romilkimab Biosimilar – Anti-IL13, IL4 mAb – Research Grade” Cancel reply
Reviews
There are no reviews yet.